Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr. Marshall
After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of Novartis Building on NIBR foundation, Dr. Marshall to shape next era of biomedical innovation and continue Novartis leadership in R&D Novartis today announced that James (Jay) E. Bradner, M.D., will step down from the Executive Committee of Novartis (ECN), effective October 31st after seven years leading research at Novartis. Fiona H.